Every Form 4 that Revelation Biosciences, Inc. (REVB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow REVB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full REVB filings page.
REVELATION BIOSCIENCES, INC. (symbol: REVB) is the issuer of record for a Form 4 filing submitted to the SEC.
REVELATION BIOSCIENCES, INC. (REVB) reported that director Lakhmir S. Chawla acquired 32,011 shares of common stock on August 17, 2026 via a restricted stock award granted at $0.00 per share under the company’s 2021 Equity Incentive Plan. Following this grant, Chawla holds 44,169 shares directly. The award vests 50% on the two-year anniversary and 50% on the four-year anniversary of the grant date, subject to continued service, with potential acceleration upon certain performance milestones.
REVELATION BIOSCIENCES, INC. (REVB) reported that its Chief Financial Officer, Chester S. Zygmont III, received a restricted stock award of 208,073 shares of Common Stock under the company’s 2021 Equity Incentive Plan. The award vests with 50% on the two-year anniversary of the grant date and the remaining 50% on the four-year anniversary, subject to continued service and possible acceleration upon performance milestones. On the same date, Zygmont made a bona fide gift of 208,073 shares to The Zygmont Family Trust, which now holds 300,136 shares indirectly, and an affiliated LLC holds an additional 2 shares indirectly.
REVELATION BIOSCIENCES, INC. (symbol: REVB) is the issuer of record for a Form 4 filing submitted to the SEC.
REVELATION BIOSCIENCES, INC. (symbol: REVB) is the issuer of record for a Form 4 filing submitted to the SEC.
Revelation Biosciences, Inc. CEO James Rolke reported a mandatory tax-related share disposition. On the vesting of restricted stock awards, the issuer sold 10,115 shares of common stock on his behalf solely to cover required tax withholding obligations.
The weighted average sale price was $1.13 per share, with individual trades between $1.12 and $1.14. After this tax-withholding transaction, Rolke directly holds 214,738 shares of common stock. The footnotes state he did not exercise investment discretion over these sales.
Revelation Biosciences Chief Financial Officer reports a routine tax-related share sale through a trust. On the reported date, 13,285 shares of common stock were disposed of at a weighted average price of $1.10 per share to satisfy required tax withholding on vested restricted stock awards. The filing states this transaction was mandatory and that the CFO did not exercise investment discretion. After this tax-withholding disposition, an indirect trust holding stands at 92,063 shares of common stock, and an affiliated LLC holds 2 additional common shares indirectly.
Revelation Biosciences director Jess Roper reported a mandatory tax-related share sale. On February 3, 2026, the issuer sold 1,591 shares of common stock on Roper’s behalf to cover tax obligations arising from vested restricted stock awards. The weighted average sale price was $1.85 per share, with individual trades ranging from $1.84 to $1.88. After this transaction, Roper directly beneficially owned 12,828 common shares. All share amounts reflect a 1-for-4 reverse stock split that became effective on January 28, 2026.
Revelation Biosciences director Lakhmir S. Chawla had 2,261 common shares sold on February 3, 2026 to cover taxes on vesting restricted stock. The issuer sold the shares on the director’s behalf at a weighted average price of $1.85 per share.
After this mandatory tax-withholding transaction, Chawla beneficially owned 12,158 common shares directly. All share figures reflect a 1-for-4 reverse stock split that became effective on January 28, 2026.
Revelation Biosciences director Jennifer Carver reported a routine share sale tied to tax withholding. On February 3, 2026, 1,661 shares of common stock were sold at a weighted average price of $1.87 per share, solely to cover tax obligations from vesting restricted stock awards.
After this mandatory transaction, Carver beneficially owned 12,758 shares of Revelation Biosciences common stock on a direct basis. All share amounts reflect a 1-for-4 reverse stock split effective January 28, 2026.
Revelation Biosciences, Inc. reported an insider transaction for Chief Executive Officer and director James Rolke. On February 3, 2026, the company sold 8,521 shares of common stock on his behalf at a weighted average price of $1.86 per share.
The sale was made solely to satisfy required tax withholding obligations arising from the vesting of restricted stock awards and was described as mandatory, with no investment discretion exercised by Rolke. After the transaction, he beneficially owned 224,853 shares of common stock, reflecting a 1-for-4 reverse stock split effective January 28, 2026.
Revelation Biosciences, Inc. Chief Financial Officer Chester S. Zygmont III reported a mandatory sale of 13,100 shares of common stock on February 4, 2026. The issuer sold these shares on his behalf solely to cover tax withholding from vesting restricted stock awards.
The weighted average sale price was $1.65 per share, with individual trades ranging from $1.63 to $1.66. All share figures reflect a 1-for-4 reverse stock split effective January 28, 2026. After the transaction, 105,348 shares are held indirectly by The Zygmont Family Trust and 2 shares are held indirectly by Czeslaw Capital Fund, LLC, both entities associated with the CFO.
Revelation Biosciences, Inc. insider filing shows its Chief Executive Officer and director, James Rolke, receiving a large equity grant. On 01/08/2026, he was awarded 532,829 shares of common stock at $0.90 per share, reported as an acquisition of non-derivative securities. These shares are described as Restricted Stock Units under the company’s 2021 Equity Incentive Plan, which vest quarterly over two years from the grant date.
Following this grant, Rolke is reported to beneficially own 933,489 shares of Revelation Biosciences common stock, held directly. The filing reflects routine equity compensation for a senior executive, with vesting tied to continued service over the two-year period.
Revelation Biosciences, Inc. Chief Financial Officer Chester S Zygmont III reported an indirect equity award through a family trust. On 01/08/2026, The Zygmont Family Trust received 78,145 shares of common stock as restricted stock units under the 2021 Equity Incentive Plan at $0.90 per share, vesting quarterly over two years from the grant date. Following this award, the trust indirectly held 473,790 shares of common stock for his benefit, with additional indirect holdings disclosed through Czeslaw Capital Fund, LLC.
Revelation Biosciences director Jennifer Carver reported an equity award of 41,981 shares of common stock on January 8, 2026. The filing shows these were granted at a stated price of $0.90 per share and are identified in a footnote as restricted stock units issued under the company’s 2021 Equity Incentive Plan. The award vests quarterly over one year from the grant date, meaning portions of the grant will settle into shares over four installments.
After this grant, Carver beneficially owns 57,669 shares of Revelation Biosciences common stock, all held directly. The filing reflects her status as a director of the company and indicates the transaction was reported by a single reporting person.
Revelation Biosciences director Jess Roper reported receiving an equity award of 41,981 shares of common stock on January 8, 2026 at a price of $0.90 per share. After this grant, Roper directly beneficially owns 57,667 shares of the company’s common stock.
The award is described as a restricted stock unit grant under the 2021 Equity Incentive Plan, which vests quarterly over one year from the grant date. The filing also reflects an existing direct holding of 15,686 common shares, separate from the new restricted stock unit award.
Revelation Biosciences director Lakhmir S. Chawla reported an equity grant. On January 8, 2026, he acquired 41,981 shares of common stock at $0.90 per share, reported as an award under transaction code “A.” After this grant, he beneficially owned 57,667 shares of Revelation Biosciences common stock held directly.
The award represents a restricted stock unit grant under the 2021 Equity Incentive Plan, which vests quarterly over one year from the grant date. The filing reflects his status as a director of Revelation Biosciences, Inc. (ticker REVB) and indicates this was a Form 4 filed for a single reporting person.
Revelation Biosciences (REVB) director reported an equity grant. On 10/29/2025, the insider acquired 15,625 shares of common stock (Code A) at $1.28 per share under the 2021 Equity Incentive Plan. The award vests 100% on January 28, 2026. Following the grant, the reporting person beneficially owned 15,686 shares, held directly.
Revelation Biosciences (REVB) reported an insider equity grant. On 10/29/2025, CEO and Director James Rolke acquired 390,614 shares of common stock as a restricted stock grant under the 2021 Equity Incentive Plan.
The award vests quarterly over one year from the grant date. Following the transaction, Rolke beneficially owned 400,660 shares, held directly.
Revelation Biosciences (REVB) reported an insider equity award. A company director acquired 15,625 shares of Common Stock on 10/29/2025, reported at a $1.28 price per share, as a restricted stock grant under the 2021 Equity Incentive Plan.
The grant vests 100% on January 28, 2026. Following the transaction, the reporting person beneficially owned 15,688 shares, held directly.
Revelation Biosciences (REVB) reported an insider equity award for its Chief Financial Officer, Chester S. Zygmont III. On 10/29/2025, the CFO acquired 390,614 shares of common stock as a restricted stock grant under the 2021 Equity Incentive Plan at a stated price of $1.28 per share. The award vests quarterly over one year from the date of grant.
Following the reported transaction, the filing lists 395,645 shares of common stock indirectly held by The Zygmont Family Trust, and additional small indirect holdings of 5,026 shares by the trust and 5 shares by Czeslaw Capital Fund, LLC. The filing indicates the use of indirect ownership structures (trust and LLC) and confirms the CFO’s status as an officer.
Revelation Biosciences (REVB) reported an insider equity award. Director Jess Roper acquired 15,625 shares of Common Stock on 10/29/2025 at $1.28 per share, coded as an acquisition. Following the transaction, the director beneficially owned 15,686 shares, held directly.
The shares were a Restricted Stock Grant under the 2021 Equity Incentive Plan and vest 100% on January 28, 2026.